Literature DB >> 10205643

Potential of low molecular mass chitosan as a DNA delivery system: biocompatibility, body distribution and ability to complex and protect DNA.

S C Richardson1, H V Kolbe, R Duncan.   

Abstract

Cationic polymers have the potential for DNA complexation and it is recognised that they may be useful as non-viral vectors for gene delivery. Highly purified chitosan fractions of < 5000 Da (N1), 5000-10,000 Da (N2) and > 10,000 Daltons (N3) were prepared and characterised in respect of their cytotoxicity, ability to cause haemolysis, ability to complex DNA as well as to protect DNA from nuclease degradation. Also the biodistribution of 125I-labelled chitosans was followed at 5 and 60 min after intravenous injection into male Wistar rats. All chitosan fractions displayed little cytotoxicity against CCRF-CEM and L132 cells (IC50 > 1 mg/ml), and they were not haemolytic (< 15% lysis after 1 and 5 h). Chitosan-DNA interaction at a charge ration of 1:1 was much greater than seen for poly(L-lysine) and complexation resulted in inhibition of DNA degradation by DNase II: 99.9 +/- 0.1, 99.1 +/- 1.5 and 98.5 +/- 2.0% for N1, N2 and N3, respectively. After intravenous injection, all the chitosans showed rapid blood clearance, the plasma levels at 1 h being 32.2 +/- 10.5% of recovered dose for N1 and 2.6 +/- 0.5% of recovered dose for N3. Liver accumulation was molecular mass dependent, being 26.5 +/- 4.9% of the recovered dose for N1 and 82.7 +/- 1.9% of the recovered dose for N3. The observations that the highly purified chitosan fractions used were neither toxic nor haemolytic, that they have the ability to complex DNA and protect against nuclease degradation and that low molecular weight chitosan can be administered intravenously without liver accumulation suggest there is potential to investigate further low molecular weight chitosans as components of a synthetic gene delivery system.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10205643     DOI: 10.1016/s0378-5173(98)00378-0

Source DB:  PubMed          Journal:  Int J Pharm        ISSN: 0378-5173            Impact factor:   5.875


  47 in total

1.  Intracellular trafficking and decondensation kinetics of chitosan-pDNA polyplexes.

Authors:  Marc Thibault; Surendra Nimesh; Marc Lavertu; Michael D Buschmann
Journal:  Mol Ther       Date:  2010-07-13       Impact factor: 11.454

Review 2.  Applying horizontal gene transfer phenomena to enhance non-viral gene therapy.

Authors:  Jacob J Elmer; Matthew D Christensen; Kaushal Rege
Journal:  J Control Release       Date:  2013-08-30       Impact factor: 9.776

3.  Long-term stability of chitosan-based polyplexes.

Authors:  Kristine Romøren; Astrid Aaberge; Gro Smistad; Beate J Thu; Oystein Evensen
Journal:  Pharm Res       Date:  2004-12       Impact factor: 4.200

4.  Preparation and blood coagulation evaluation of chitosan microspheres.

Authors:  Qi Zhao Wang; Xi Guang Chen; Zi Xiang Li; Song Wang; Cheng Sheng Liu; Xiang Hong Meng; Chen Guang Liu; Ying Hui Lv; Le Jun Yu
Journal:  J Mater Sci Mater Med       Date:  2007-10-04       Impact factor: 3.896

5.  Enhancement of immunological activity of CpG ODN by chitosan gene carrier.

Authors:  Yi Xiang; Qingsong Yu; Zhi Qi; Zhengde Du; Shunqing Xu; Huafeng Zhang
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2007-04

6.  Effects of alkylated-chitosan-DNA nanoparticles on the function of macrophages.

Authors:  L X Liu; C N Song; L P Song; H L Zhang; X Dong; X G Leng
Journal:  J Mater Sci Mater Med       Date:  2008-11-20       Impact factor: 3.896

Review 7.  Degradable and bioresorbable polymers in surgery and in pharmacology: beliefs and facts.

Authors:  Michel Vert
Journal:  J Mater Sci Mater Med       Date:  2008-09-25       Impact factor: 3.896

8.  Improved mucoadhesion and cell uptake of chitosan and chitosan oligosaccharide surface-modified polymer nanoparticles for mucosal delivery of proteins.

Authors:  Sathish Dyawanapelly; Uday Koli; Vimisha Dharamdasani; Ratnesh Jain; Prajakta Dandekar
Journal:  Drug Deliv Transl Res       Date:  2016-08       Impact factor: 4.617

9.  Chitosan Interferon-gamma Nanogene Therapy for Lung Disease: Modulation of T-Cell and Dendritic Cell Immune Responses.

Authors:  Xiaoyuan Kong; Gary R Hellermann; Weidong Zhang; Prasanna Jena; Mukesh Kumar; Aruna Behera; Sumita Behera; Richard Lockey; Shyam S Mohapatra
Journal:  Allergy Asthma Clin Immunol       Date:  2008-09-15       Impact factor: 3.406

10.  Enhanced gene delivery mediated by low molecular weight chitosan/DNA complexes: effect of pH and serum.

Authors:  Surendra Nimesh; Marc M Thibault; Marc Lavertu; Michael D Buschmann
Journal:  Mol Biotechnol       Date:  2010-10       Impact factor: 2.695

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.